Philadelphia Inquirer: Merck, GlaxoSmithKline Join GAVI in Pricing Agreement for HPV Vaccine in Developing Countries

While drug companies celebrate price reductions that will allow girls in poor countries to be vaccinated against cervical cancer for $14 per patient, these prices are still out of reach for millions of people, MSF's Kate Elder explains.

View external media